Abstract 5148: Analysis of HER2 prevalence by RNA expression across solid tumors
Authors: Katherine Moxley, Emilie Scherrer, Martin Bontrager, Samantha Whitman, Naomi R. Schwartz, Chithra Sangli, Seung Won Hyun, Halla Nimeiri, Jonathan Ball, Charu Aggarwal
Journal: Cancer Research (2024)

Abstract Background: The frequency of HER2 expression in solid tumors other than breast (BC) and gastric cancer (GC) is not well defined. This study describes the frequency of HER2 expression by correlating HER2 IHC/ISH and ERBB2 mRNA levels by NGS in tumor samples of patients with locally advanced/metastatic (LA/m) BC or GC and applying those findings to predict HER2 expression in other solid tumors. Methods: De-identified records from NGS-tested patients with LA/m BC, GC, HNSCC, NSCLC, endometrial, and ovarian cancers in the Tempus database from 2015 - 2021 were analyzed. Patients with BC and GC who underwent HER2 IHC/ISH testing were categorized as: RNA-zero (IHC0), -low (IHC1+, IHC2+/ISH-), and -positive (HER2+; IHC2+/ISH+, IHC3+). To identify thresholds separating HER2 subgroups, a logistic regression model was fit to NGS and IHC status data in BC and GC. These thresholds were applied to other solid tumors to predict the distribution of HER2 expression. HER2 amplification and mutation rates were evaluated in the Tempus NGS data. Results: Logistic regression modeling used 3,898 samples. HER2+ samples had the highest IHC-to-RNA agreement at 80% (BC) and 81% (GC) compared to HER2 low and zero samples which ranged ~56-75% agreement. When applying thresholds identifying RNA-low and RNA-positive sample to other tumors (N = 4,726), the models predicted up to 33% (BC thresholds) or 56% (GC thresholds) of tumors express HER2 at levels that may be detectable (Table 1). Conclusions: A notable amount of solid tumors apart from BC or GC have RNA expression that may correspond to HER2 IHC ≥1+. This opens the possibility for novel agents such as HER2-directed antibody drug conjugates to impact patient care in several tumor types. Further IHC testing in these populations are needed to corroborate our results. Table 1. ERBB2 (HER2) Categories in Solid Tumors HER2 Status HNSCC (N = 630) NSCLC (N = 2945) OC (N = 855) EC (N = 295) NGS BC thresholds ERBB2 Log2(TPM+1) RNA-Zero 589 (93.5%) 1,974 (67.0%) 626 (73.2%) 205 (69.5%) RNA-Low 33 (5.2%) 853 (29.0%) 214 (25.0%) 64 (21.7%) RNA-Positive 8 (1.3%) 118 (4.0%) 15 (1.8%) 26 (8.8%) RNA-Low + RNA-positive 41 (6.5%) 971 (33.0%) 229 (26.8%) 90 (30.5%) NGS GC thresholds ERBB2 Log2(TPM+1) RNA-zero 492 (78.1%) 1,345 (45.7%) 395 (46.2%) 130 (44.1%) RNA-Low 124 (19.7%) 1,190 (40.4%) 384 (44.9%) 127 (43.1%) RNA-Positive 14 (2.2%) 410 (13.9%) 76 (8.9%) 38 (12.9%) RNA-Low + RNA-positive 138 (21.9%) 1,600 (54.3%) 460 (53.8%) 165 (55.9%) DNA Amplification Unamplified 622 (98.7%) 2,911 (98.8%) 843 (98.6%) 277 (93.9%) Amplified 8 (1.3%) 34 (1.2%) 12 (1.4%) 18 (6.1%) DNA mutation Wild-Type 623 (98.9%) 2,916 (99.0%) 850 (99.4%) 287 (97.3%) Mutated 7 (1.1%) 29 (1.0%) 5 (0.6%) 8 (2.7%) NGS: next-generation sequencing; HNSCC: head and neck squamous cell carcinoma; NSCLC: non-small cell lung cancer; OC: ovarian cancer; EC: endometrial cancer; TPM: transcripts per million Citation Format: Katherine Moxley, Emilie Scherrer, Martin Bontrager, Samantha Whitman, Naomi R. Schwartz, Chithra Sangli, Seung Won Hyun, Halla Nimeiri, Jonathan Ball, Charu Aggarwal. Analysis of HER2 prevalence by RNA expression across solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5148.